Myasthenia gravis-associated neuromyelitis optica-like disease: An immunological link between the central nervous system and muscle?

Archives of Neurology

Volumn 68, Issue 12, 2011, Pages 1557-1561

  Vaknin Dembinsky, Adi ^a   Abramsky, Oded ^a   Petrou, Panayiota ^a   Ben Hur, Tamir ^a   Gotkine, Marc ^a   Brill, Livnat ^a   Brenner, Talma ^a   Argov, Zohar ^a   Karussis, Dimitrios ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; EVOKED VISUAL RESPONSE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; THYMOMA; THYMUS HYPERPLASIA; WHITE MATTER;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; COHORT STUDIES; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMYELITIS OPTICA; THYMOMA; THYMUS NEOPLASMS; YOUNG ADULT;

EID: 83455225214     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.200     Document Type: Article

References (37)

1. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-1810.
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368. (Pubitemid 32224355)
3. Christensen PB, Jensen TS, Tsiropoulos I, et al. Associated autoimmune diseases in myasthenia gravis: a population-based study. Acta Neurol Scand. 1995; 91(3):192-195.
4. Tola MR, Caniatti LM, Casetta I, et al. Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy. Acta Neurol Scand. 1994;90(5):318- 323.
5. Patten BM. Myasthenia gravis: review of diagnosis and management. Muscle Nerve. 1978;1(3):190-205.
6. Levin N, Karussis D, Abramsky O. Parkinson's disease associated with myasthenia gravis: a report of 4 cases. J Neurol. 2003;250(6):766-767. (Pubitemid 36718372)
7. Steiner I, Brenner T, Soffer D, Argov Z. Involvement of sites other than the neuromuscular junction in myasthenia gravis. In: Lisak RP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York, NY: Marcel Dekker; 1994: 277-294.
8. Kay CS, Scola RH, Lorenzoni PJ, Jarius S, Arruda WO, Werneck LC. NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci. 2008;275(1-2):148-150.
9. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol. 2006;13(6):655-658. (Pubitemid 43873639)
10. Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol. 2006;63(6):851-856. (Pubitemid 43882293)
11. Martikainen K, Nikoskelainen E, Frey H. Neuromyelitis optica in a patient with myasthenia gravis [in Finnish]. Duodecim. 1986;102(3):178-182.
12. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364 (9451):2106-2112. (Pubitemid 39626806)
13. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65 (7):913-919. (Pubitemid 352008474)
14. Gomes D, Agasse A, Thieaposbaud P, Delrot S, Geroaposs H, Chaumont F. Aquaporins are multifunctional water and solute transporters highly divergent in living organisms. Biochim Biophys Acta. 2009;1788(6):1213-1228.
15. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4):473-477. (Pubitemid 41186945)
16. Weinshenker BG. Neuromyelitis optica is distinct from multiple sclerosis. Arch Neurol. 2007;64(6):899-901. (Pubitemid 46919849)
17. Wakayama Y. Aquaporin expression in normal and pathological skeletal muscles: a brief review with focus on AQP4. J Biomed Biotechnol. 2010;2010:731569.
18. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357(9274): 2122-2128. (Pubitemid 32607461)
19. Chan KH, Kwan JS, Ho PW, et al. Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. J Neuroimmunol. 2010; 227(1-2):178-184.
20. Halliday AM, McDonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet. 1972;1(7758):982-985.
21. Jablonski EM, Webb AN, McConnell NA, Riley MC, Hughes FM Jr. Plasma membrane aquaporin activity can affect the rate of apoptosis but is inhibited after apoptotic volume decrease. Am J Physiol Cell Physiol. 2004;286(4):C975- C985. (Pubitemid 38543826)
22. Mygland A, Vincent A, Newsom-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000; 57(4):527-531. (Pubitemid 30212127)
23. Uzawa A, Mori M, Iwai Y, et al. Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci. 2009;287 (1-2):105-107.
24. Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology. 2006;67(5):881-883. (Pubitemid 44394210)
25. Shiao YM, Lee CC, Hsu YH, et al. Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia. J Neuroimmunol. 2010;221(1-2):101-106.
26. Park MJ, Kim YA, Lee SS, Kim BC, Kim MK, Cho KH. Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. J Korean Med Sci. 2004;19(1):134-136.
27. Gerli R, Paganelli R, Cossarizza A, et al. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin Immunol. 1999; 103(5, pt 1):865-872. (Pubitemid 29297590)
28. Simpson JA. Immunological disturbances in myasthenia gravis with a report of Hashimoto's disease developing after thymectomy. J Neurol Neurosurg Psychiatry. 1964;27:485-492.
29. Kinoshita I, Nagasato K, Shibayama K, et al. A case of systemic lupus erythematosus following thymectomy in myasthenia gravis [in Japanese]. Nippon Naika Gakkai Zasshi. 1988;77(12):1894-1895.
30. Petersen P, Lund J. Systemic lupus erythematosus following thymectomy for myasthenia gravis. Dan Med Bull. 1969;16(6):179-181.
31. O'Sullivan SS, Mullins GM, Neligan A, McNamara B, Galvin RJ. Acquired generalised neuromyotonia, cutaneous lupus erythematosus and alopecia areata in a patient with myasthenia gravis. Clin Neurol Neurosurg. 2007;109(4):374-375. (Pubitemid 46441636)
32. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001;182:58-67. (Pubitemid 33070207)
33. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G; PNS Euro-network. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330-335.
34. Briani C, Cagnin A, Blandamura S, Altavilla G. Multiple paraneoplastic diseases occurring in the same patient after thymomectomy. J Neurooncol. 2010;99 (2):287-288.
35. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur J Neurol. 2008;15(10):1029-1033.
36. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008;65(5):629-632. (Pubitemid 351679657)
37. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009;39(1):87-90.